K. Shah

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann et al. · The Journal of Rheumatology · 2016 · 210 citations

Medicine, Internal Medicine, Pharmacotherapy +15

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

Kristian Reich, Melinda Gooderham, L. Green et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 198 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology · 2017 · 192 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Real-world burden of comorbidities in US patients with psoriasis

K. Shah, L. Mellars, Arun Changolkar et al. · Journal of the American Academy of Dermatology · 2017 · 89 citations · Full text

Medicine, Dermatology, Clinical Epidemiology +13

Real-world burden of comorbidities in US patients with psoriatic arthritis

K. Shah, Maria Paris, L. Mellars et al. · RMD Open · 2017 · 81 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +13